Leukemia and Lymphoma
Journal Title
- Leukemia and Lymphoma
ISSN
- E 1029-2403 | P 1042-8194 | 1029-2403 | 1042-8194
Publisher
- Taylor & Francis
Listed on(Coverage)
| JCR | 1997-2019 |
|---|---|
| SJR | 1999-2019 |
| CiteScore | 2011-2019 |
| SCIE | 2010-2021 |
| CC | 2016-2021 |
| SCOPUS | 2017-2020 |
| MEDLINE | 2016-2021 |
| EMBASE | 2016-2020 |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- ENGLAND
Aime & Scopes
- Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor. Leukemia & Lymphoma is also dedicated to education in the form of reviews, commentaries, conference summaries and emerging drug profiles. All submissions are subject to peer review and disclosure requirements, as stipulated by the International Committee of Medical Journal Editors (ICMJE). Rapid turnaround time for reviews as well as fast online publication assure timely access to accepted publications. The journal provides a premier reference source for physicians and scientists interested in clinical, translational, and laboratory research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders.